Osocimab (BAY 1213790) is a potent anti-FXIa antibody with a Ki value of 2.4 nM and an EC50 value of 0.2 nM.Osocimab may reduce thrombosis through FXI inhibition.Osocimab is often used as an XI factor inhibitor, has an inhibitory effect on thrombin generation, has an anticoagulant effect, and is used in the study of thromboembolic diseases. Thromboembolic Diseases

Substrate cleavage (FXIa mediated):1.2 nM, FIX activation:16 nM

In human plasma, Osocimab (1.4 nM-1 μM; 30 min) demonstrated inhibition of thrombin production, as well as FXIa-mediated FIX activation (or FIX conversion) with an IC50 of 16 nM and FXIa-mediated substrate cleavage with an IC50 of 1.2 nM [1]. Osocimab, at a concentration of 22.05 mg/mL, inhibited activation of the intrinsic pathway-mediated coagulation cascade [1].